

Head Office

Pushpak, 1st Floor
Panchvati Circle
Motilal Hirabhai Road
Ahmedabad 380006
Gujarat, India
Phone +91 79 26445106

Factory

Village Merda-Ardraj
Taluka Kadi
District Mehsana
Gujarat 382721, India
Phone +91 2764 285 502
+91 2764 285 453

Email mail@hester.in
Toll Free 1800 233 7937
www.hester.in

CIN L99999GJ1987PLC022333

4 November 2022

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

To,
National Stock Exchange of India Limited
Exchange Plaza,
Bandra - Kurla Complex,
Bandra (E), Mumbai 400 051

Scrip Code: 524669

Symbol: HESTERBIO

Dear Sir/ Madam:

Subject: Outcome of Board Meeting

This is with reference to our letter dated 22 October 2022 intimating the date of the Board Meeting for consideration of the Standalone and Consolidated Unaudited Financial Results for the quarter and ended 30 September 2022.

Pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors, in their meeting held today, approved the standalone and consolidated unaudited financial results for the quarter and half year ended 30 September 2022, as recommended by the Audit Committee of the Board.

We attach herewith:

- 1) The approved standalone and consolidated unaudited financial results and limited review reports
- 2) A Press Release issued in this regard

We will be publishing an extract of the results in the newspaper as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Board Meeting commenced at 11:04 a.m. (IST) and concluded at 12:13 p.m. (IST).

You are requested to take the above information on your record.

Sincerely
For Hester Biosciences Limited



Vinod Mali
Company Secretary & Compliance Officer

Enclosure: As above

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS PERIOD ENDED 30 SEPTEMBER 2022

Amount in INR Million

Sr. No.	Particulars	Quarter Ended			Six Months Period Ended		Year Ended
		30 September 2022	30 June 2022	30 September 2021	30 September 2022	30 September 2021	31 March 2022
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	Income						
1	Revenue from Operations	720.03	505.28	565.94	1,225.31	1,150.99	2,193.51
2	Other Income	21.77	12.34	13.22	34.11	23.54	46.57
3	Total income	741.80	517.62	579.16	1,259.42	1,174.53	2,240.08
4	Expenses						
	(a) Cost of material consumed	68.62	60.34	113.10	128.96	188.02	349.31
	(b) Purchases of stock-in-trade	139.09	86.29	89.21	225.38	154.30	392.97
	(c) Change in inventories of finished goods, traded goods and work in progress	8.49	14.69	(58.00)	23.18	(25.56)	(125.26)
	(d) Employee benefits expense	130.41	99.19	98.53	229.60	197.53	391.19
	(e) Finance cost	17.43	12.69	3.53	30.12	7.20	24.68
	(f) Depreciation and amortisation expense	23.37	23.93	23.22	47.30	46.20	95.02
	(g) Other expenses	215.60	152.79	151.75	368.39	283.86	579.61
	Total expenses	603.01	449.92	421.34	1,052.93	851.55	1,707.52
5	Profit before tax	138.79	67.70	157.82	206.49	322.98	532.56
6	Tax Expense						
	Current tax	35.24	20.17	37.74	55.41	87.56	142.53
	Deferred tax	0.10	(2.52)	2.34	(2.42)	(4.69)	(5.14)
	Total tax expense	35.34	17.65	40.08	52.99	82.87	137.39
7	Profit after tax	103.45	50.05	117.74	153.50	240.11	395.17
8	Other Comprehensive Income						
	Items that will not be reclassified to Profit or Loss						
	Remesurement Gain/(Loss) on Defined Benefit Plans	0.24	(0.53)	(2.94)	(0.29)	(2.22)	(2.10)
	Income tax impact	(0.06)	0.13	0.74	0.07	0.56	0.53
	Total Other Comprehensive Income	0.18	(0.40)	(2.20)	(0.22)	(1.66)	(1.57)
9	Total Comprehensive Income for the period / year	103.63	49.65	115.54	153.28	238.45	393.60
10	Paid-up equity share capital						85.07
11	Other Equity						2,599.27
12	Earnings Per Share (Face Value of INR 10 each) (Not Annualised) - Basic & Diluted (INR)	12.16	5.88	13.84	18.04	28.22	46.45

STATEMENT OF UNAUDITED STANDALONE ASSETS AND LIABILITIES AS AT 30 SEPTEMBER 2022

Amount in INR Million

Particulars	As at 30 September 2022	As at 31 March 2022
ASSETS		
Non-current assets		
(a) Property Plant & Equipment	1,005.32	839.50
(b) Capital Work-in-Progress	1,103.29	802.24
(c) Other Intangible Assets	3.12	3.59
(d) Intangible Assets under Development	15.88	16.85
(e) Financial Assets		
(i) Investments	646.89	646.89
(ii) Other Financial Assets	44.41	60.41
(f) Other Non-current Assets	220.64	210.22
Total Non-current Assets	3,039.55	2,579.70
Current assets		
(a) Inventories	707.40	707.34
(b) Financial Assets		
(i) Trade Receivables	735.80	569.16
(ii) Cash and Cash Equivalents	19.03	15.28
(iii) Bank Balances other than (ii) above	11.08	4.53
(iv) Loans	60.91	58.76
(v) Other Financial Assets	152.85	146.64
(c) Other Current Assets	188.01	163.01
Total Current Assets	1,875.08	1,664.72
Total Assets	4,914.63	4,244.42
EQUITY AND LIABILITIES		
Equity		
(a) Share capital	85.07	85.07
(b) Other equity	2,667.48	2,599.27
	2,752.55	2,684.34
Liabilities		
Non-current liabilities		
(a) Financial Liabilities		
(i) Borrowings	901.11	732.49
(ii) Other Financial Liabilities	7.03	5.53
(b) Other Non Current Liabilities	240.00	-
(c) Non Current Provision	14.14	10.77
(d) Deferred Tax Liabilities (Net)	60.50	62.92
Total Non-current Liabilities	1,222.78	811.71
Current liabilities		
(a) Financial Liabilities		
(i) Borrowings	657.86	486.64
(ii) Trade Payables		
-Total outstanding dues of micro enterprises and small enterprises	63.89	19.88
-Total outstanding dues of creditors other than micro enterprises and small enterprises	124.89	90.39
(iii) Other Financial Liabilities	49.70	125.88
(b) Other Current Liabilities	15.26	13.81
(c) Provisions	3.37	2.39
(d) Current Tax Liabilities	24.33	9.38
Total Current Liabilities	939.30	748.37
Total Liabilities	2,162.08	1,560.08
Total Equity and Liabilities	4,914.63	4,244.42

STATEMENT OF UNAUDITED STANDALONE CASH FLOWS FOR SIX MONTHS PERIOD ENDED 30 SEPTEMBER 2022

Amount in INR Million

Particulars	Six Months Period Ended	
	30 September 2022	30 September 2021
	Unaudited	Unaudited
A. Cash Flow from operating activities		
Profit Before Tax	206.49	322.98
Adjustments for:		
Depreciation and amortisation Expense	47.30	46.20
Provision for doubtful debt	1.85	2.28
Bad debts written off	0.26	19.79
(Profit) / Loss on sale of property, plant & equipment	(0.16)	0.56
Profit on buy-back of shares by subsidiary	-	(2.26)
Interest expense	9.11	6.17
Unrealised foreign exchange loss / (gain)	21.47	-
Interest income	(11.25)	(9.15)
Operating profit before working capital changes	275.07	386.57
Adjustments for:		
Trade receivables	(164.41)	(151.43)
Inventories	(0.06)	(15.25)
Other assets	(25.00)	27.09
Trade payables	78.31	(11.62)
Other current liabilities	1.45	(13.92)
Provisions	4.35	2.51
Loans	(2.15)	(2.19)
Other financial Liability	1.26	2.42
Other financial assets	2.70	(7.25)
Cash Generated from Operations	171.52	216.93
Income tax paid (net)	(40.39)	(66.08)
Net cash generated from operating activities (A)	131.13	150.85
B. Cash flow from investing activities		
Capital expenditure on Property, Plant and Equipment, including capital advances and capital work-in-progress and on intangible assets	(551.26)	(105.88)
Proceeds from Sale of Property, Plant and Equipment	0.26	-
Payment towards investment in subsidiaries	-	-
Payment towards investment in joint venture entity	-	-
Proceeds from buy-back of shares by subsidiary	-	9.79
Interest received	2.95	1.54
Bank / margin money deposits withdrawn / (Investment) (Net)	8.55	9.51
Net cash used in investing activities (B)	(539.50)	(85.04)
C. Cash flow from financing activities		
Proceeds from long term borrowings	227.81	-
Repayment of long term borrowings	(36.52)	(50.76)
Proceeds/(Repayment) of Short-term Borrowings (net)	83.92	75.53
Government grant received	240.00	-
Interest Paid	(18.02)	(6.17)
Dividend Paid	(85.07)	(85.07)
Net cash generated from / (used in) financing activities (C)	412.12	(66.47)
Net increase / (decrease) in cash and cash equivalents (A) + (B) + (C)	3.75	(0.66)
Cash and cash equivalents at the beginning of the period	15.28	12.44
Cash and cash equivalents at the end of the period	19.03	11.78

Notes:

- 1 The standalone financial results of Hester Biosciences Limited (the "Company") have been reviewed by the Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 4 November 2022.
- 2 The Statutory Auditors have carried out limited review of the standalone financial results of the Company for the quarter and six months period ended 30 September 2022.
- 3 Following are the details of segment wise revenue, results, segment assets and liabilities:

Amount in INR Million

Particulars	Quarter Ended			Six Months Period Ended		Year Ended
	30 September 2022	30 June 2022	30 September 2021	30 September 2022	30 September 2021	31 March 2022
Segment Revenue						
a. Poultry Healthcare	354.52	383.70	413.83	738.22	894.87	1,712.31
b. Animal Healthcare	365.51	121.58	152.11	487.09	256.12	481.20
Total Revenue from Operations	720.03	505.28	565.94	1,225.31	1,150.99	2,193.51
Segment Results						
a. Poultry Healthcare	80.28	85.26	148.74	165.54	319.90	537.88
b. Animal Healthcare	119.65	(14.99)	6.89	104.66	(5.76)	(16.81)
Total Segment Results	199.93	70.27	155.63	270.20	314.14	521.07
a. Finance Costs	17.43	12.69	3.53	30.12	7.20	24.68
b. Other unallocable expenditure/(income) (Net)	43.71	(10.12)	(5.72)	33.59	(16.04)	(36.17)
Profit before Tax	138.79	67.70	157.82	206.49	322.98	532.56
Segment Assets						
a. Poultry Healthcare	2,556.28	2,552.90	1,932.76	2,556.28	1,932.76	2,362.17
b. Animal Healthcare	487.03	307.14	295.23	487.03	295.23	310.29
Unallocated Assets	1,871.32	1,782.41	778.51	1,871.32	778.51	1,571.96
Total	4,914.63	4,642.45	3,006.50	4,914.63	3,006.50	4,244.42
Segment Liabilities						
a. Poultry Healthcare	137.13	182.63	135.92	137.13	135.92	151.37
b. Animal Healthcare	79.14	23.72	21.83	79.14	21.83	46.12
Unallocated Liabilities	1,945.81	1,702.11	319.56	1,945.81	319.56	1,362.59
Total	2,162.08	1,908.46	477.31	2,162.08	477.31	1,560.08

Note:

Unallocated assets and liabilities includes capital work in-progress, capital advances and capital creditors related to Human Vaccine Project as the same is yet to be capitalised.

For and on behalf of the Board of Directors


Rajiv Gandhi
 CEO & Managing Director
 DIN: 00438037

 Place: Ahmedabad
 Date: 4 November 2022

Chandulal M. Shah & Co.

CHARTERED ACCOUNTANTS

A/6, 6th Floor, Wing-A, Safal Profitaire, Opp. Prahladnagar Garden, Corporate Road, Prahladnagar, Ahmedabad-380015.
Tel. : 079-2960 1085 • (M) 90330 34430 • E-mail : cmshah@cmshah.com • Website : www.cmshah.com

Independent Auditor's review report on Quarterly Unaudited Standalone Financial Results of Hester Biosciences Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors of
Hester Biosciences Limited

1. We have reviewed the accompanying statement of unaudited financial results of **Hester Biosciences Limited** for the quarter ended on September 30, 2022 and year to date results for the period from April 01, 2022 to September 30, 2022 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed u/s 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in accordance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a Report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognized accounting principles and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed or that it contains any material misstatement.

For Chandulal M. Shah & Co.
Chartered Accountants
FRN No. 101698W

Arpit D. Shah

Arpit D. Shah
Partner

M. No. 135188

UDIN:221351888B2VFL3529

Place: Ahmedabad

Date: November 04, 2022



STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS PERIOD ENDED 30 SEPTEMBER 2022

Amount in INR Million

Sr. No.	Particulars	Quarter Ended			Six Months Period Ended		Year Ended
		30 September 2022	30 June 2022	30 September 2021	30 September 2022	30 September 2021	31 March 2022
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	Income						
1	Revenue from Operations	731.53	506.95	626.62	1,238.48	1,228.48	2,350.06
2	Other Income	44.49	31.23	14.24	75.72	37.72	137.41
3	Total income	776.02	538.18	640.86	1,314.20	1,266.20	2,487.47
4	Expenses						
	(a) Cost of material consumed	129.57	115.59	174.52	245.16	296.41	606.53
	(b) Purchases of stock-in-trade	71.67	29.24	23.53	100.91	48.78	126.18
	(c) Change in inventories of finished goods, traded goods and work in progress	12.70	(1.27)	(36.53)	11.43	(5.08)	(105.56)
	(d) Employee benefits expense	150.98	118.47	111.17	269.45	224.05	453.32
	(e) Finance cost	24.55	16.01	7.42	40.56	16.02	40.64
	(f) Depreciation and amortisation expense	50.30	50.60	30.51	100.90	62.80	165.81
	(g) Other expenses	239.16	170.62	178.35	409.78	318.05	669.76
	Total expenses	678.93	499.26	488.97	1,178.19	961.03	1,956.68
5	Profit before Share of Profit of Joint Venture entity and Tax	97.09	38.92	151.89	136.01	305.17	530.79
6	Share of Profit in Joint Venture entity	5.63	15.71	-	21.34	-	4.23
7	Profit before tax	102.72	54.63	151.89	157.35	305.17	535.02
8	Tax Expense						
	Current tax	36.86	21.06	39.47	57.92	90.06	147.84
	Deferred tax	(0.17)	(2.03)	1.14	(2.20)	(6.36)	(7.66)
	Total tax Expense	36.69	19.03	40.61	55.72	83.70	140.18
9	Profit after tax	66.03	35.60	111.28	101.63	221.47	394.84
10	Other Comprehensive Income						
	Items that will not be reclassified to Profit or Loss						
	Remeasurement Gain/(Loss) on Defined Benefit Plans	0.24	(0.53)	(2.94)	(0.29)	(2.22)	(2.10)
	Income tax impact	(0.06)	0.13	0.74	0.07	0.56	0.53
	Items that will be reclassified to Profit or Loss						
	Foreign Currency Translation Reserve	8.28	8.87	2.64	17.15	4.99	9.78
	Income Tax Impact	-	-	-	-	-	-
	Total Other Comprehensive Income	8.46	8.47	0.44	16.93	3.33	8.21
11	Total Comprehensive Income for the period/year	74.49	44.07	111.72	118.56	224.80	403.05
12	Profit for the period/year attributable to:						
	(i) Owners of the Company	69.42	39.68	106.23	109.10	231.13	393.20
	(ii) Non Controlling Interest	(3.39)	(4.08)	5.05	(7.47)	(9.66)	1.64
13	Other Comprehensive Income for the period/year attributable to:						
	(i) Owners of the Company	8.46	8.47	0.44	16.93	3.33	8.21
	(ii) Non Controlling Interest	-	-	-	-	-	-
14	Total Comprehensive Income for the period/year attributable to:						
	(i) Owners of the Company	77.88	48.15	106.67	126.03	234.46	401.41
	(ii) Non Controlling Interest	(3.39)	(4.08)	5.05	(7.47)	(9.66)	1.64
15	Paid-up equity share capital						85.07
16	Other Equity						2,514.78
17	Earnings Per Share (Face Value of INR 10 each) (Not Annualised) - Basic & Diluted (INR)	7.77	4.18	13.08	11.95	26.03	46.41

STATEMENT OF UNAUDITED CONSOLIDATION ASSETS AND LIABILITIES AS AT 30 SEPTEMBER 2022

Amount in INR Million

Particulars	As at 30 September 2022	As at 31 March 2022
ASSETS		
Non-current assets		
(a) Property Plant & Equipment	2,554.19	2,368.13
(b) Capital Work-in-Progress	1,103.29	802.24
(c) Other Intangible Assets	3.12	3.59
(d) Intangible Assets under Development	15.88	16.85
(e) Financial Assets		
(i) Investments	233.07	212.38
(ii) Other Financial Assets	44.56	60.56
(f) Other Non-current Assets	221.97	210.23
Total Non-current Assets	4,176.08	3,673.98
Current assets		
(a) Inventories	767.35	753.82
(b) Financial Assets		
(i) Trade Receivables	695.18	552.80
(ii) Cash and Cash Equivalents	170.81	247.50
(iii) Bank Balances other than (ii) above	11.08	4.53
(iv) Loans	60.91	60.80
(v) Other Financial Assets	152.80	150.10
(c) Other Current Assets	203.70	178.08
Total Current Assets	2,061.83	1,947.63
Total Assets	6,237.91	5,621.61
EQUITY AND LIABILITIES		
Equity		
(a) Share capital	85.07	85.07
(b) Other equity	2,555.77	2,514.78
Equity Attributable to Owners	2,640.84	2,599.85
Non Controlling Interest	66.63	74.09
Total Equity	2,707.47	2,673.94
Liabilities		
Non-current liabilities		
(a) Financial Liabilities		
(i) Borrowings	1,902.25	1,645.44
(ii) Lease Liabilities	56.32	52.70
(iii) Other Financial Liabilities	7.03	5.66
(b) Other Non Current Liabilities	397.17	197.08
(c) Non Current Provision	14.14	12.72
(d) Deferred Tax Liabilities (Net)	62.90	65.10
Total Non-current Liabilities	2,439.81	1,978.70
Current liabilities		
(a) Financial Liabilities		
(i) Borrowings	708.56	580.27
(ii) Lease Liabilities	3.51	3.27
(iii) Trade Payables	266.33	180.18
(iv) Other Financial Liabilities	65.17	141.54
(b) Other Current Liabilities	15.50	51.51
(c) Provisions	6.02	2.82
(d) Current Tax Liabilities	25.54	9.38
Total Current Liabilities	1,090.63	968.97
Total Liabilities	3,530.44	2,947.67
Total Equity and Liabilities	6,237.91	5,621.61

STATEMENT OF UNAUDITED CONSOLIDATED CASH FLOWS FOR THE SIX MONTHS PERIOD ENDED 30 SEPTEMBER 2022

Amount in INR Million

Particulars	Six Months Period Ended	
	30 September 2022	30 September 2021
	Unaudited	Unaudited
A. Cash Flow from operating activities		
Profit Before Tax	157.35	305.17
Adjustments for:		
Depreciation and amortisation Expense	100.90	62.80
Share of profit in joint venture entity	(21.34)	-
Exceptional items	-	-
Provision for doubtful debt	1.85	2.28
Bad debts written off	0.26	19.79
(Profit) / Loss on sale of property, plant & equipment	(0.16)	0.56
Amortisation of deferred grant	(39.91)	(16.19)
Interest expense	15.32	14.99
Unrealised foreign exchange loss / (gain)	21.47	-
Interest income	(11.25)	(9.12)
Operating profit before working capital changes	224.50	380.28
Adjustments for:		
Trade receivables	(140.16)	(142.51)
Inventories	(13.53)	(0.60)
Other assets	(25.62)	(40.77)
Trade payables	85.95	(39.11)
Other liabilities	(32.16)	(1.65)
Provisions	4.62	2.51
Loans	(0.11)	(2.19)
Other financial liability	1.01	10.86
Other financial assets	2.70	(0.50)
Cash Generated From Operations	107.21	166.32
Income tax paid (net)	(42.80)	(66.26)
Net cash generated from operating activities (A)	64.41	100.06
B. Cash flow from investing activities		
Capital expenditure on Property, Plant and Equipment, including capital advances and capital work-in-progress and on intangible assets	(636.74)	(137.19)
Proceeds from Sale of Property, Plant and Equipment	0.26	-
Payment towards investment in joint venture entity	-	-
Interest received	2.95	1.51
Bank / margin money deposits withdrawn / (Investment) (Net)	8.55	9.51
Net cash used in investing activities (B)	(624.97)	(126.17)
C. Cash flow from financing activities		
Proceeds from long term borrowings	259.06	-
Repayment of long term borrowings	(22.50)	(119.06)
Proceeds/(Repayment) of Short-term Borrowings (net)	83.92	144.25
Proceeds from Issue of Share Capital in subsidiary entities from Non-controlling interest shareholders	-	3.98
Payment to Non-controlling interest shareholders for buy-back of shares in subsidiary	-	(8.03)
Government grant received	240.00	-
Interest Paid	(20.25)	(14.99)
Dividend Paid	(85.07)	(85.07)
Net cash generated from / (used in) financing activities (C)	455.16	(78.92)
Exchange rate fluctuation arising on consolidation (D)	28.71	10.40
Net increase/ (decrease) in cash and cash equivalents (A) + (B) + (C) + (D)	(76.69)	(94.63)
Cash and cash equivalents at the beginning of the period	247.50	212.69
Cash and cash equivalents at the end of the period	170.81	118.06

Notes:

- The consolidated financial results of Hester Biosciences Limited (the "Company") and its subsidiaries (together referred as the "Group") and its joint venture entity have been reviewed by the Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 04 November 2022.
- The Statutory Auditors have carried out limited review of the consolidated financial results of the Group for the quarter and six months period ended 30 September 2022.
- Following are the details of consolidated segment wise revenue, results, segment assets and liabilities:

Amount in INR Million

Particulars	Quarter Ended			Six Months Period Ended		Year Ended
	30 September 2022	30 June 2022	30 September 2021	30 September 2022	30 September 2021	31 March 2022
Segment Revenue						
a. Poultry Healthcare	348.43	383.91	454.50	732.34	909.82	1,718.31
b. Animal Healthcare	383.10	123.04	172.12	506.14	387.25	631.75
Total Revenue from Operations	731.53	506.95	626.62	1,238.48	1,297.07	2,350.06
Segment Results						
a. Poultry Healthcare	79.47	92.63	145.16	172.10	279.62	547.38
b. Animal Healthcare	88.45	(41.41)	21.88	47.04	26.34	9.06
Total Segment Results	167.92	51.22	167.04	219.14	305.96	556.44
a. Finance Costs	24.55	16.01	7.42	40.56	16.02	40.64
b. Share of Profit in Joint Venture Entity	5.63	15.71	-	21.34	-	4.23
c. Other unallocable expenditure/(income) (Net)	46.28	(3.71)	7.73	42.57	(15.23)	(14.99)
Profit before Tax	102.72	54.63	151.89	157.35	305.17	535.02
Segment Assets						
a. Poultry Healthcare	2,622.65	2,557.15	2,014.45	2,622.65	2,014.45	2,360.77
b. Animal Healthcare	2,157.77	2,071.44	1,948.87	2,157.77	1,948.87	2,123.38
Unallocated Assets	1,457.49	1,362.47	339.77	1,457.49	339.77	1,137.46
Total	6,237.91	5,991.06	4,303.09	6,237.91	4,303.09	5,621.61
Segment Liabilities						
a. Poultry Healthcare	207.15	255.53	160.14	207.15	160.14	219.44
b. Animal Healthcare	232.64	288.91	376.85	232.64	376.85	343.50
Unallocated Liabilities	3,090.65	2,728.61	1,266.92	3,090.65	1,266.92	2,384.73
Total	3,530.44	3,273.05	1,803.91	3,530.44	1,803.91	2,947.67

Note:


Unallocated assets and liabilities includes capital work in-progress, capital advances and capital creditors related to Human Vaccine Project as the same is yet to be capitalised.

- Key numbers of the standalone financial results of the Company for the quarter and six months period ended 30 September 2022 are as under:

Particulars	Quarter Ended			Six Months Period Ended		Year Ended
	30 September 2022	30 June 2022	30 September 2021	30 September 2022	30 September 2021	31 March 2022
Total income	741.80	517.62	579.16	1,259.42	1,174.53	2,240.08
Profit before tax	138.79	67.70	157.82	206.49	322.98	532.56
Profit after Tax	103.45	50.05	117.74	153.50	240.11	395.17
Total comprehensive income	103.63	49.65	115.54	153.28	238.45	393.60

 The Standalone Financial Results are available at the Company's website www.hester.in and on the website of the stock exchanges www.bseindia.com and www.nseindia.com.

For and on behalf of the Board of Directors


Rajiv Gandhi
 CEO & Managing Director
 DIN: 00438037

Place: Ahmedabad

Date: 4 November 2022

Chandulal M. Shah & Co.

CHARTERED ACCOUNTANTS

A/6, 6th Floor, Wing-A, Safal Profitaire, Opp. Prahladnagar Garden, Corporate Road, Prahladnagar, Ahmedabad-380015.
Tel. : 079-2960 1085 • (M) 90330 34430 • E-mail : cmshah@cmshah.com • Website : www.cmshah.com

Independent Auditor's review report on Quarterly Unaudited Consolidated financial results of Hester Biosciences Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors of
Hester Biosciences Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results of Hester Biosciences Limited (the "Holding company") and its subsidiaries and joint venture entity (the Holding, its subsidiaries and joint venture entity together referred to as the "Group") for the quarter ended on September 30, 2022 and year to date results for the period April 01, 2022 to September 30, 2022 (the "Statement"), attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed u/s 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a Report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

We have also performed procedures in accordance with the Circular No. CIR/CFD/CMDI/44/2019 dated March 29, 2019, issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The statement includes the results of the following subsidiaries and joint venture:

Sr. No.	Name of the Company	Relationship
1	Texas Lifesciences Private Limited	Subsidiary
2	Hester Biosciences Nepal Private Limited	Subsidiary
3	Hester Biosciences Africa Limited	Subsidiary
4	Hester Biosciences Kenya Limited	Subsidiary
5	Hester Biosciences Tanzania Limited	Subsidiary
6	Thrishool Exim Limited	Joint Venture Entity

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognized accounting principles and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



6. The unaudited consolidated financial results include the interim financial statements of 2 subsidiaries which have been reviewed by other auditors, whose interim financial statements reflect total assets of INR 510.24 million as at September 30, 2022, total income of INR 76.31 million and INR 141.17 million, total net profit / (loss) after tax of INR (11.00) million and INR (23.42) million and total comprehensive income / (loss) of INR (11.00) million and of INR (23.42) million for the quarter ended on September 30, 2022 and for the period from April 01, 2022 to September 30, 2022 respectively and net cash outflows of INR 24.36 million for the period from April 01, 2022 to September 30, 2022 as considered in the consolidated unaudited financial results. The interim financial statements of these subsidiaries have been reviewed by the other auditors whose reports have been furnished to us, and our conclusion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the report of such other auditors and the procedures performed by us as stated in paragraph 3 above.
7. The unaudited consolidated financial results include the interim financial statements of 3 subsidiaries which have not been reviewed by their auditors, whose interim financial statements reflect total assets of INR 1,440.83 million as at September 30, 2022, total income of INR 27.11 million and INR 52.61 million, total net profit / (loss) after tax of INR (30.50) million and INR (50.07) million and total comprehensive loss of INR (30.32) million and of INR (50.19) million for the quarter ended on September 30, 2022 and for the period from April 01, 2022 to September 30, 2022 respectively and net cash outflows of INR 56.09 million for the period from April 01, 2022 to September 30, 2022 as considered in the consolidated unaudited financial results. The management has certified these financial statements and other financial information.
8. The accompanying Statement includes the group's share of Net Profit after tax of INR 5.63 million and INR 21.34 million for the quarter ended on September 30, 2022 and for the period from April 01, 2022 to September 30, 2022, in respect of the joint venture entity. The management has certified these interim financial statements and other financial information of the joint venture entity.
9. Certain of these subsidiaries and joint venture entity are located outside India whose financial results have been prepared in accordance with accounting principles generally accepted in their respective countries ('local GAAP'). The Holding Company's management has converted the financial results of such subsidiaries and joint venture entity from local GAAP to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Holding Company's management. Our conclusion, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and joint venture entity, is based on the conversion adjustments prepared by the management of the Holding Company and reviewed by us.

Our conclusion on the statement in respect of the matters stated in paragraph 6, 7, 8 and 9 above is not modified with respect to our reliance on the work done and the reports of the other auditors and the financial statements and financial information certified by the Management.

For Chandulal M. Shah & Co.
Chartered Accountants
FRN No. 101698W

Arpit D. Shah

Arpit D. Shah
Partner

M. No. 135188

UDIN: 22135188882VFY2196

Place: Ahmedabad
Date: November 04, 2022



Press Release

4 November 2022

Hester Biosciences Limited Q2 & H1 FY23 Results

Standalone revenue up by 27% and 6% for Q2 and H1 FY23

Consolidated revenue up by 17% and 1% for Q2 and H1 FY23

Hester today announced the unaudited financial results for Q2 & H1 FY23.

Standalone Financial Highlights

Division Revenues

(INR Million)

Division	Q2			H1		
	FY23	FY22	Change %	FY23	FY22	Change %
Poultry Healthcare	354.52	413.83	-14%	698.73	858.38	-19%
Animal Healthcare	365.51	152.11	140%	487.09	256.12	90%
Product Sales	720.03	565.94	27%	1,185.82	1,114.50	6%
License & services fees	-	-	-	39.49	36.49	8%
Revenue from Operations	720.03	565.94	27%	1,225.31	1,150.99	6%

Product Category Revenues

(INR Million)

Divisions	Q2			H1		
	FY23	FY22	Change %	FY23	FY22	Change %
Vaccines	527.83	424.11	24%	835.23	861.26	-3%
Health Products	192.20	141.83	36%	350.59	253.24	38%
Total Product Sales	720.03	565.94	27%	1,185.82	1,114.50	6%

- The Company has achieved the highest quarterly sales in its history. The substantial increase in the current quarter sales has offset the degrowth in Q1 FY23.
- The increase in sales can be largely attributed to:
 - A spurt in the demand for the Goat Pox Vaccine to control the outbreak of Lumpy Skin Disease (LSD) in cattle in the country. With no specific vaccine available for LSD in India, Goat Pox Vaccine was permitted for use as a heterologous vaccine to immunize cattle against LSD. Hester has been and continues to be the dominant supplier of the Goat Pox Vaccine to various State Government bodies and in the private sector.
 - A growth of 36% in the health products business. This has been achieved from new product introductions and territorial expansion.
- The company's Vaccine sales have increased by 24% in Q2 while it shows a degrowth in H1 due to significant low sales in Q1 for poultry vaccines. The poultry industry continues to be under pressure to high feed costs and low product realisations. Health Products sales has increased by 36%.

Profitability Analysis

(INR Million)

Particulars	Q2			H1		
	FY23	FY22	Change %	FY23	FY22	Change %
Gross Profit margin on Product Sales	70%	75%	-5%	68%	72%	-4%
Operating EBIDTA	157.82	171.35	-8%	249.80	352.84	-29%
Operating EBIDTA Margin	22%	30%	-8%	20%	31%	-11%
PAT (excl. OCI)	103.45	117.74	-12%	153.50	240.11	-36%
PAT Margin	14%	21%	-7%	13%	21%	-8%
EPS (In INR, not annualised)	12.16	13.84	-12%	18.04	28.22	-36%

- The gross margins have reduced by 5% in Q2 and 4% in H1 FY23, on account of:
 - Increase in proportion of sales of health products that have lower margins; and
 - Change in product mix.
- Operating EBITDA and PAT margin have declined due to:
 - Increased travel and sales promotion expenses in H1 FY23 versus H1 FY22, which were significantly lower due to Covid travel restrictions.
 - Increased market development cost in Animal Health (driven by market expansion and new launches) and launch of the new Petcare Division.
 - Increase in finance cost due to increase in borrowing and foreign exchange fluctuation costs.

Going further

The Company's focus on the various segments would be as follows:

Vaccines:

- With LSD as a new challenge in the cattle industry, we would be focusing on LSD awareness programs as well as promote the immunisation against LSD through our Goat Pox vaccine.
- Indian Veterinary Research Institute (IVRI) has developed an LSD vaccine as well as an Avian Influenza vaccine technology. Hester has bid to acquire both these technologies and develop its own LSD and Avian Influenza vaccines respectively.
- The current stress on the poultry industry has induced farmers to turn to more scientific farming. Hester aims at increasing the reach of its Technical Services team to help poultry farmers become more cost efficient via using more scientific methods as well as ensuring proper immunization against various diseases.
- GoI would soon be commencing its PPR disease immunization program in sheep & goat. Hester being the successful bidder for the supply of PPR vaccine, these supplies are expected to start from Q4.

Health Products:

- Though vaccines have been our core strength, the enormous, big market for animal health products has induced us to look at this segment for a higher top-line growth. We shall continue our endeavour to grow this division by increasing our field force in size as well as by improving the productivity of the field force.
- With the increase in our product range, we would now be looking at international markets as vaccines have contributed to over 97% of exports.
- Health products being low in margins, it is our continuous endeavour to improve the gross margins.

Petcare division:

- The Company launched a new division for Petcare during Q1 with 10 products focused on therapies like anti-infectives, parasitocides, specialty nutrition and grooming with key focus on quality and efficacy.
- Moving further, activities related to market expansion and penetration by increasing field force and introduction of new products are ongoing.

3. We have divided our distribution network into four regions to primarily cover all the metro cities initially and are working on market expansion into further cities.
4. More products are planned for launch in Q4. These products will be in the categories of therapeutics, namely NSAIDs and De-wormers.

India is the fastest growing pet market in the world, internally growing at 14%. Indian pet industry is set to touch INR 100 billion by 2025. Considering this, the Petcare Division will emerge as a steady long term growth driver.

Production and capacity expansion initiatives

1. Bulk antigen (Drug Substance) production capacity expansion project is completed and capitalized in the books during the quarter.
2. Expansion of the Fill-Finish (Drug Product) capacity is expected to be completed by Q4 FY23. These 2 expansions will double the production capacity in vaccines.

Status on Hester's initiative towards manufacturing the Drug Substance for Covaxin, a Covid-19 vaccine

1. Hester, in consortium with Gujarat Biotechnology Research Centre (GBRC), Government of Gujarat (GoG), has entered into an agreement with Bharat Biotech to manufacture the Drug Substance for Covaxin under the Mission Covid Suraksha Scheme of Government of India.
2. The project is to manufacture Drug Substance equivalent of up to 7 million doses per month.
3. The construction of BSL-3 facility is completed. Commissioning activities is ongoing. The facility is expected to be ready for commercial operation by end of FY23.
4. This facility can be repurposed to handle other micro-organisms beyond Covid-19.

Consolidated Financial Highlights

(INR Million)

Particulars	Q2			H1		
	FY23	FY22	Change %	FY23	FY22	Change %
Revenue from operations	731.53	626.62	17%	1,238.48	1,228.48	1%
Net Profit (excl. OCI)	66.03	111.28	-41%	101.63	221.47	-54%
EPS (In INR, not annualised)	7.77	13.08	-41%	11.95	26.03	-54%

- Consolidated results also include operations of subsidiaries at Nepal and Tanzania.
- Hester Africa recorded a revenue of INR 1.5 million upon commencement of the commercial sales operations within Tanzania during Q2. Moving further, in the coming quarters, export operations will also pick the pace up and contribute towards the overall growth.

**Hester Biosciences Limited****Head Office**

Pushpak, 1st Floor
Panchvati Circle
Motilal Hirabhai Road
Ahmedabad 380006
Gujarat, India
Phone +91 79 26445106

Factory

Village Merda-Ardraj
Taluka Kadi
District Mehsana
Gujarat 382721, India
Phone +91 2764 285 502
+91 2764 285 453

Email mail@hester.in
Toll Free 1800 233 7937
www.hester.in

CIN L99999GJ1987PLC022333

About Hester Biosciences Limited:

Hester Biosciences Limited is one of the India's leading poultry and animal vaccine manufacturing company, since 1997. Hester operates in two broad product segments

1. Vaccines
 2. Health products
- It is the world's largest manufacturer and supplier of PPR vaccine, having approximately 75% of the world market
 - It is now the second largest poultry vaccine manufacturer, with approximately 35% market share in India.

Hester's vaccine capabilities include multiple platforms such as Chick Embryo Origin, Continuous Cell line, Tissue Culture and Fermentation based live as well as inactivated vaccines.

Hester recently forayed into human vaccines by building a new BSL III drug substance manufacturing facility intended to manufacture Covid-19 and such other human vaccines.

Hester recently launched the Petcare Division with a view to focus on needs of companion animals.

Hester recognises the vision of ONE HEALTH, and works on improving the health of animals by enabling better health for human beings.

For more information, please visit www.hester.in